Trial reportThe Journal of clinical endocrinology and metabolism2013
Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
Trial report in The Journal of clinical endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03396315 (Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis), which is not on this map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis
Who cites it
47 citing papers in PubMed, 83 citations in OpenAlex.
- Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab.The Journal of clinical endocrinology and metabolism · 2022Trial
- Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.The Journal of clinical endocrinology and metabolism · 2022Trial
- Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.The Journal of clinical endocrinology and metabolism · 2020Trial
- Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.The Journal of clinical endocrinology and metabolism · 2015Trial
- Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study.The Journal of clinical endocrinology and metabolism · 2014Trial
- Postpartum timing of teriparatide initiation and BMD response in pregnancy- and lactation-associated osteoporosis: an observational study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Observational
- Mechanisms limiting the long-term anabolic effects of teriparatide (PTH 1-34) on bone.JBMR plus · 2026Review
- Pregnancy and lactation-associated osteoporosis: insights from an online self-reported patient survey.Archives of osteoporosis · 2026Article
- Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Effective strategies for pregnancy and lactation-associated osteoporosis: teriparatide use in focus.Endocrine · 2024Review
- The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics · 2023Review
- Bridging the Gap: Pregnancy-And Lactation-Associated Osteoporosis.Diagnostics (Basel, Switzerland) · 2023Review
- Measuring Drug Therapy Effect on Osteoporotic Fracture Risk by Trabecular Bone Lacunarity: The LOTO Study.Biomedicines · 2023Article
- Recent Insights into Pregnancy and Lactation-Associated Osteoporosis (PLO).International journal of women's health · 2023Review
- Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.Acta bio-medica : Atenei Parmensis · 2022Review
- Short Cyclic Regimen With Parathyroid Hormone (PTH) Results in Prolonged Anabolic Effect Relative to Continuous Treatment Followed by Discontinuation in Ovariectomized Rats.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Dilemmas in the Management of Osteoporosis in Younger Adults.JBMR plus · 2022Review
- Case report: Early-onset osteoporosis in a patient carrying a novel heterozygous variant of theFrontiers in endocrinology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
contextPremenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture.
objectiveThe purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP.
designThis was an open-label pilot study.
settingThe setting was a tertiary care referral center. PATIENTS: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD.
interventionTeriparatide was administered at 20 μg daily for 18 to 24 months.
main outcome measuresThe primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide.
resultsBMD increased at the spine (10.8 ± 8.3% [SD]), total hip (6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%) (all P < .001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71% increase in trabecular bone stiffness (P < .02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm²/mm/y; P < .001) and higher serum IGF-1 (208 ± 54 vs 157± 44 ng/mL; P = .03).
conclusionsTeriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.